Can we risk transplantation across positive complement-dependent cytotoxicity crossmatches in pediatric patients?

Octavio E Pajaro; Daniel S Ramon; Andrés Jaramillo

doi:10.1111/ajt.14986

Can we risk transplantation across positive complement-dependent cytotoxicity crossmatches in pediatric patients?

Am J Transplant. 2018 Sep;18(9):2107-2108. doi: 10.1111/ajt.14986. Epub 2018 Jul 30.

Authors

Octavio E Pajaro¹, Daniel S Ramon², Andrés Jaramillo²

Affiliations

¹ Department of Cardiothoracic Surgery, Mayo Clinic, Phoenix, AZ, USA.
² Department of Laboratory Medicine and Pathology, Mayo Clinic, Phoenix, AZ, USA.

PMID: 29947127
DOI: 10.1111/ajt.14986

No abstract available

Keywords: clinical trial; editorial/personal viewpoint; heart transplantation/cardiology; immunosuppressant; immunosuppression/immune modulation; organ transplantation in general; panel reactive antibody (PRA); plasmapheresis/plasma exchange.

Publication types

Editorial
Comment

MeSH terms

Antilymphocyte Serum
Child
Heart Transplantation*
Humans
Incidence
Tissue Donors

Substances

Antilymphocyte Serum